JP2021533199A5 - - Google Patents
Info
- Publication number
- JP2021533199A5 JP2021533199A5 JP2021529260A JP2021529260A JP2021533199A5 JP 2021533199 A5 JP2021533199 A5 JP 2021533199A5 JP 2021529260 A JP2021529260 A JP 2021529260A JP 2021529260 A JP2021529260 A JP 2021529260A JP 2021533199 A5 JP2021533199 A5 JP 2021533199A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- complex according
- transferrin receptor
- nucleotides
- dmpk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025004577A JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713914P | 2018-08-02 | 2018-08-02 | |
| US62/713,914 | 2018-08-02 | ||
| US201862779161P | 2018-12-13 | 2018-12-13 | |
| US62/779,161 | 2018-12-13 | ||
| US201962855761P | 2019-05-31 | 2019-05-31 | |
| US62/855,761 | 2019-05-31 | ||
| US201962858888P | 2019-06-07 | 2019-06-07 | |
| US62/858,888 | 2019-06-07 | ||
| US201962859672P | 2019-06-10 | 2019-06-10 | |
| US62/859,672 | 2019-06-10 | ||
| PCT/US2019/044987 WO2020028861A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004577A Division JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533199A JP2021533199A (ja) | 2021-12-02 |
| JP2021533199A5 true JP2021533199A5 (enExample) | 2022-08-09 |
| JP7705793B2 JP7705793B2 (ja) | 2025-07-10 |
Family
ID=69230803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Active JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP2025004577A Active JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004577A Active JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210308272A1 (enExample) |
| EP (1) | EP3829596A4 (enExample) |
| JP (2) | JP7705793B2 (enExample) |
| KR (1) | KR20210081323A (enExample) |
| CN (1) | CN112955154A (enExample) |
| AU (2) | AU2019314538B2 (enExample) |
| CA (1) | CA3108287A1 (enExample) |
| IL (2) | IL280425B2 (enExample) |
| MX (1) | MX2021001283A (enExample) |
| SG (1) | SG11202100925VA (enExample) |
| WO (1) | WO2020028861A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018378812B2 (en) | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021142217A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
| SI4126066T1 (sl) * | 2020-03-27 | 2026-04-30 | Avidity Biosciences, Inc. | Sestavki in postopki zdravljenja mišične distrofije |
| JP2023535078A (ja) * | 2020-07-23 | 2023-08-15 | ダイン セラピューティクス，インコーポレーテッド | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
| KR20230046297A (ko) * | 2020-07-23 | 2023-04-05 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| CA3189065A1 (en) * | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
| IL303332A (en) * | 2020-12-04 | 2023-07-01 | Dyne Therapeutics Inc | Antibody-oligonucleotide complexes and their uses |
| CA3202832A1 (en) * | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
| CA3226457A1 (en) * | 2021-07-30 | 2023-02-02 | Amy WALKER | Nanoparticles and peptides for the delivery of cargos to muscle cells |
| WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| WO2023034870A2 (en) | 2021-09-01 | 2023-03-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dmpk expression |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| EP2595663A4 (en) | 2010-07-19 | 2014-03-05 | Isis Pharmaceuticals Inc | MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION |
| CA2907072A1 (en) * | 2012-03-16 | 2013-09-19 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of dmpk |
| EP2900821B1 (en) | 2012-09-25 | 2020-04-01 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| CN105142672B (zh) * | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| TW201536329A (zh) * | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
-
2019
- 2019-08-02 AU AU2019314538A patent/AU2019314538B2/en active Active
- 2019-08-02 IL IL280425A patent/IL280425B2/en unknown
- 2019-08-02 CA CA3108287A patent/CA3108287A1/en active Pending
- 2019-08-02 IL IL321905A patent/IL321905A/en unknown
- 2019-08-02 SG SG11202100925VA patent/SG11202100925VA/en unknown
- 2019-08-02 KR KR1020217005992A patent/KR20210081323A/ko active Pending
- 2019-08-02 WO PCT/US2019/044987 patent/WO2020028861A1/en not_active Ceased
- 2019-08-02 EP EP19843799.8A patent/EP3829596A4/en active Pending
- 2019-08-02 US US17/264,905 patent/US20210308272A1/en not_active Abandoned
- 2019-08-02 MX MX2021001283A patent/MX2021001283A/es unknown
- 2019-08-02 CN CN201980062906.7A patent/CN112955154A/zh active Pending
- 2019-08-02 JP JP2021529260A patent/JP7705793B2/ja active Active
-
2025
- 2025-01-14 JP JP2025004577A patent/JP7847681B2/ja active Active
- 2025-05-30 AU AU2025204039A patent/AU2025204039A1/en active Pending